Translational Neuroimmunology of Multiple Sclerosis: From Disease Mechanisms to Clinical Applications

Multiple Sclerosis (MS) is the most common disabling neurological disease of young adults, although it can also affect children and adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the amount of damage and the nerves that are affected. People with severe cases of MS may lose the ability to walk or speak clearly. Although there is not currently a cure for MS, therapies can help treat MS attacks, manage symptoms and reduce progress of the disease. This book will provide an overview of recent findings and knowledge of the Neuroimmunology of Multiple Sclerosis and the translation of this research to immunotherapy treatment. Chapters will include the disease pathogenesis of MS as a basis for development of immunotherapies, immunological markers, pharmacogenetics and responses to therapy. Immunomodulatory therapies currently in practice and future therapeutic strategies on the horizon will also be discussed. Edited by renowned leaders in the field, this book will be a great resource for basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology. Provides an overview of recent findings and knowledge of the neuroimmunology of Multiple Sclerosis and the translation of this research to immunotherapy treatmentEdited by renowned leaders in the field of neuroimmunology and Multiple SclerosisA great resource for basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology INDICE: Part I. Disease pathogenesis as a basis for development of Immunotherapies-update for Multiple Sclerosis 1. Immunopathogenesis- update 2. Disease subtypes :Clinical and Immunological (CIS, RR-MS;PP-MS; ADEM, NMO... ) 3. Childhood MS 4. Immunogenetics of MS Part II. Markers of Disease activity and Response to Therapy 1. Clinical and MRI criteria 2. Immunological markers 3. Pharmacogenetics, Tailored therapeutics and Personalized Medicine 4. Patient Reported Outcomes (PROs) and Participatory Medicine Part III.  Immunomodulatory therapies in practice 1. Copoaxone / GA 2. Interferons 3. Tysabri (and the usage of anti JCV Ab as a marker) 4. Gilenya 5. Tecfidera (BG-12) 6. Others (also/optional: Vitamin D, Immunosuppression, symptomatic treatments, etc.)  Part IV. Therapeutic Strategies on the Horizon 1. Overview of ongoing Clinical Trials 2. Is cell therapy a valid option for MS (MSCs; iPS, etc.) 3. Protective Autoimmunity and MS 4. Combination therapies & Future Directions

• ISBN: 978-0-12-801914-6
• Editorial: Academic Press
• Encuadernacion: Cartoné
• Páginas: 200
• Fecha Publicación: 15/02/2016
• Nº Volúmenes: 1
• Idioma: Inglés